y3dgz5d2

Property	Value
?:abstract	SARS-CoV-2 induced hypercytokinemia and inflammation are critically associated with COVID-19 disease severity. Baricitinib, a clinically approved JAK1/2 inhibitor, is currently being investigated in COVID-19 clinical trials. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages and tissues was not reduced with baricitinib. Type-I IFN antiviral responses and SARS-CoV-2-specific T-cell responses remained similar between the two groups. Animals treated with baricitinib showed reduced inflammation, decreased lung infiltration of inflammatory cells, reduced NETosis activity, and more limited lung pathology. Importantly, baricitinib treated animals had a rapid and remarkably potent suppression of lung macrophages production of cytokines and chemokines responsible for inflammation and neutrophil recruitment. These data support a beneficial role for, and elucidate the immunological mechanisms underlying, the use of baricitinib as a frontline treatment for inflammation induced by SARS-CoV-2 infection.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/y3dgz5d2_hasAnnotation_C0021368> <https://research.tib.eu/covid-19/entity/y3dgz5d2_hasAnnotation_C0162633> <https://research.tib.eu/covid-19/entity/y3dgz5d2_hasAnnotation_C4330505> <https://research.tib.eu/covid-19/entity/y3dgz5d2_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Hoang%2C_Timothy_N.%3B_Pino%2C_Maria%3B_Boddapati%2C_Arun_K.%3B_Viox%2C_Elise_G.%3B_Starke%2C_Carly_E.%3B_Upadhyay%2C_Amit_A.%3B_Gumber%2C_Sanjeev%3B_Nekorchuk%2C_Michael%3B_Busman-Sahay%2C_Kathleen%3B_Strongin%2C_Zachary%3B_Harper%2C_Justin_L.%3B_Tharp%2C_Gregory_K.%3B_Pellegrini%2C_Kathryn_L.%3B_Kirejczyk%2C_Shannon%3B_Zandi%2C_Keivan%3B_Tao%2C_Sijia%3B_Horton%2C_Tristan_R.%3B_Beagle%2C_Elizabeth_N.%3B_Mahar%2C_Ernestine_A.%3B_Lee%2C_Michelle_YH.%3B_Cohen%2C_Joyce%3B_Jean%2C_Sherrie_M.%3B_Wood%2C_Jennifer_S.%3B_Connor-Stroud%2C_Fawn%3B_Stammen%2C_Rachelle_L.%3B_Delmas%2C_Olivia_M.%3B_Wang%2C_Shelly%3B_Cooney%2C_Kimberly_A.%3B_Sayegh%2C_Michael_N.%3B_Wang%2C_Lanfang%3B_Filev%2C_Peter_D.%3B_Weiskopf%2C_Daniela%3B_Silvestri%2C_Guido%3B_Waggoner%2C_Jesse%3B_Piantadosi%2C_Anne%3B_Kasturi%2C_Sudhir_P.%3B_Al-Shakhshir%2C_Hilmi%3B_Ribeiro%2C_Susan_P.%3B_Sekaly%2C_Rafick_P.%3B_Levit%2C_Rebecca_D.%3B_Estes%2C_Jacob_D.%3B_Vanderford%2C_Thomas_H.%3B_Schinazi%2C_Raymond_F.%3B_Bosinger%2C_Steven_E.%3B_Paiardini%2C_Mirko>
?:doi	<https://research.tib.eu/covid-19/entity/10.1016/j.cell.2020.11.007>
?:doi	10.1016/j.cell.2020.11.007
?:journal	Cell
?:license	els-covid
?:pdf_json_files	document_parses/pdf_json/7274328450740a5839e4e9ff18d6d851fc1b519c.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7654323>
?:pmid	<https://research.tib.eu/covid-19/entity/33278358.0>
?:pmid	33278358.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/y3dgz5d2_HAS_C0085236_PRODUCES_C0079189> <https://research.tib.eu/covid-19/entity/y3dgz5d2_HAS_C0085236_PRODUCES_C0282554> <https://research.tib.eu/covid-19/entity/y3dgz5d2_HAS_C4044947_DISRUPTS_C0021368> <https://research.tib.eu/covid-19/entity/y3dgz5d2_HAS_C4044947_TREATS_C0021368> <https://research.tib.eu/covid-19/entity/y3dgz5d2_HAS_C5203670_CAUSES_C0021368>
?:sha_id	<https://research.tib.eu/covid-19/entity/7274328450740a5839e4e9ff18d6d851fc1b519c>
?:source	Elsevier; Medline; PMC
?:title	Baricitinib treatment resolves lower airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-10

Property

Value

?:abstract

SARS-CoV-2 induced hypercytokinemia and inflammation are critically associated with COVID-19 disease severity. Baricitinib, a clinically approved JAK1/2 inhibitor, is currently being investigated in COVID-19 clinical trials. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages and tissues was not reduced with baricitinib. Type-I IFN antiviral responses and SARS-CoV-2-specific T-cell responses remained similar between the two groups. Animals treated with baricitinib showed reduced inflammation, decreased lung infiltration of inflammatory cells, reduced NETosis activity, and more limited lung pathology. Importantly, baricitinib treated animals had a rapid and remarkably potent suppression of lung macrophages production of cytokines and chemokines responsible for inflammation and neutrophil recruitment. These data support a beneficial role for, and elucidate the immunological mechanisms underlying, the use of baricitinib as a frontline treatment for inflammation induced by SARS-CoV-2 infection.

is ?:annotates of